youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
BAX:NYSE
Baxter International Inc
$25.30
arrow_downward
-1.38%(-0.36) 1D
Oct 23, 4:00:10 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAX...
Open
$25.71
High
$25.71
Low
$25.20
Mkt. cap
13.08B
Avg. vol.
6.75M
Volume
39.00
Dividend
0.16%
Quarterly dividend
$0.01
Ex-dividend date
Aug 28, 2026
52-wk high
$30.00
52-wk low
$15.73
EPS
-$2.07
Beta
0.66
Shares outstanding
517.00M
No. of employees
38K
Open
$25.71
High
$25.71
Low
$25.20
Mkt. cap
13.08B
Avg. vol.
6.75M
Volume
39.00
Dividend
0.16%
Quarterly dividend
$0.01
Ex-dividend date
Aug 28, 2026
52-wk high
$30.00
52-wk low
$15.73
EPS
-$2.07
Beta
0.66
Shares outstanding
517.00M
No. of employees
38K
News stories
From web sources and news partners
The Motley Fool
·
17 minutes ago
The Nasdaq Composite Just Plunged Almost 700 Points in One Day: Is a Stock Market Crash Imminent?
TradingView
·
1 hour ago
SPX: S&P 500 Futures Steady as Big Fed Decision Keeps a Lid on Optimism
Yahoo Finance
·
2 hours ago
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.
Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients.
Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services".
Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology. Wikipedia
About Baxter International Inc
CEOAndrew Hider
Employees37.5K
Founded1931
HeadquartersDeerfield, Illinois, United States
SectorMedical device
Websitebaxter.com
Analyst ratings
Based on 9 analysts giving stock ratings to BAX in the past 3 months
Hold
Buy
0
Hold
8
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BAX in the last 3 months.
Highest
Current $25.30
$29.00 (+14.62%)
Average
$25.89 (+2.33%)
Lowest
$20.00 (-20.95%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Christopher Pasquale Barclays | Sell | Initiated | $20.00 | -20.9% | 10/07/2026 |
Matt Miksic Barclays | Sell | Maintained | $20.00 | -20.9% | 10/07/2026 |
Joanne Wuensch Citi | Hold | Maintained | $27.00 | +6.7% | 10/05/2026 |
Travis Steed Bank of America Securities | Hold | Maintained | $28.00 | +10.7% | 08/11/2026 |
Robbie Marcus J.P. Morgan | Hold | Maintained | $26.00 | +2.8% | 08/06/2026 |
Pito Chickering Deutsche Bank | Hold | Maintained | $27.00 | +6.7% | 07/31/2026 |
Josh Jennings TD Cowen | Hold | Maintained | $29.00 | +14.6% | 07/31/2026 |
Unknown Analyst Wells Fargo | Hold | Reiterated | $23.00 | -9.1% | 07/31/2026 |
Rick Wise Stifel Nicolaus | Hold | Maintained | $28.00 | +10.7% | 07/31/2026 |
Danielle Antalffy UBS | Hold | Reiterated | $25.00 | -1.2% | 07/28/2026 |
Patrick Wood UBS | Hold | Reiterated | $25.00 | -1.2% | 07/28/2026 |
David Roman Goldman Sachs | Hold | Reiterated | $21.00 | -17% | 07/15/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $24.00 | -5.1% | 07/06/2026 |
Steven Silver Argus Research | Hold | Maintained | - | - | 05/08/2026 |
Matthew Taylor Jefferies | Hold | Reiterated | $19.00 | -24.9% | 02/12/2026 |
Next call in 3 days
Thu, Oct 29, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.52
Revenue / Est. (USD)
- / 2.91B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 2.84B | 2.97B | 2.70B | 2.96B |
Cost of goods sold | 1.81B | 2.01B | 1.80B | 1.82B |
Cost of revenue | 1.81B | 2.01B | 1.80B | 1.82B |
Research and development expenses | 115.00M | 116.00M | 124.00M | 125.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 669.00M | 675.00M | 658.00M | 642.00M |
Operating expense | 734.00M | 741.00M | 735.00M | 715.00M |
Total operating expenses | 2.55B | 2.76B | 2.54B | 2.53B |
Operating income | 287.00M | 219.00M | 163.00M | 427.00M |
Other non operating income | 2.00M | 3.00M | -1.00M | 1.00M |
EBT including unusual items | 121.00M | -756.00M | -6.00M | 158.00M |
EBT excluding unusual items | 228.00M | 161.00M | 93.00M | 364.00M |
Income tax expense | 172.00M | 279.00M | 11.00M | 23.00M |
Effective tax rate | 142.15% | -36.90% | -183.33% | 14.56% |
Other operating expenses | -50.00M | -50.00M | -47.00M | -52.00M |
Net income | -46.00M | -1.13B | -15.00M | 126.00M |
Net profit margin | -1.62% | -37.93% | -0.56% | 4.26% |
Earnings per share | 0.69 | 0.44 | 0.36 | 0.56 |
Interest and investment income | 10.00M | 11.00M | 12.00M | 13.00M |
Interest expense | -68.00M | -69.00M | -78.00M | -77.00M |
Net interest expenses | -58.00M | -58.00M | -66.00M | -64.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 524.00M | 459.00M | 400.00M | 666.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1